Pulmonary aspergillosis: Recent advances

George Richard Thompson, Thomas F. Patterson

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Aspergillosis remains a significant cause of morbidity and mortality. The spectrum of disease is diverse and ranges from noninvasive disease with an excessive immune response, such as in allergic bronchopulmonary aspergillosis (ABPA), to a lack of an immune response as seen in patients with quantitative or qualitative granulocyte deficits and subsequent invasive pulmonary aspergillosis. Noninvasive diagnostic testing has improved the time to initiation of effective antifungal therapy, and numerous agents in different therapeutic classes are now available as treatment options. Voriconazole remains the preferred agent in the treatment of invasive pulmonary aspergillosis, and recent data have increased interest in the potential of combination therapy against this often lethal infection. The role of host genetics in selecting patients that may benefit from more aggressive antifungal prophylaxis or treatment practices remains unclear but is likely to guide therapeutic choices as newer data become available.

Original languageEnglish (US)
Pages (from-to)673-681
Number of pages9
JournalSeminars in Respiratory and Critical Care Medicine
Volume32
Issue number6
DOIs
StatePublished - 2011

Fingerprint

Pulmonary Aspergillosis
Invasive Pulmonary Aspergillosis
Therapeutics
Allergic Bronchopulmonary Aspergillosis
Aspergillosis
Granulocytes
Morbidity
Mortality
Infection

Keywords

  • aspergilloma
  • Aspergillosis
  • chronic cavitary aspergillosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Pulmonary aspergillosis : Recent advances. / Thompson, George Richard; Patterson, Thomas F.

In: Seminars in Respiratory and Critical Care Medicine, Vol. 32, No. 6, 2011, p. 673-681.

Research output: Contribution to journalArticle

@article{9c3a4069b4fe4ef0af5320eab299f562,
title = "Pulmonary aspergillosis: Recent advances",
abstract = "Aspergillosis remains a significant cause of morbidity and mortality. The spectrum of disease is diverse and ranges from noninvasive disease with an excessive immune response, such as in allergic bronchopulmonary aspergillosis (ABPA), to a lack of an immune response as seen in patients with quantitative or qualitative granulocyte deficits and subsequent invasive pulmonary aspergillosis. Noninvasive diagnostic testing has improved the time to initiation of effective antifungal therapy, and numerous agents in different therapeutic classes are now available as treatment options. Voriconazole remains the preferred agent in the treatment of invasive pulmonary aspergillosis, and recent data have increased interest in the potential of combination therapy against this often lethal infection. The role of host genetics in selecting patients that may benefit from more aggressive antifungal prophylaxis or treatment practices remains unclear but is likely to guide therapeutic choices as newer data become available.",
keywords = "aspergilloma, Aspergillosis, chronic cavitary aspergillosis",
author = "Thompson, {George Richard} and Patterson, {Thomas F.}",
year = "2011",
doi = "10.1055/s-0031-1295715",
language = "English (US)",
volume = "32",
pages = "673--681",
journal = "Seminars in Respiratory and Critical Care Medicine",
issn = "1069-3424",
publisher = "Thieme Medical Publishers",
number = "6",

}

TY - JOUR

T1 - Pulmonary aspergillosis

T2 - Recent advances

AU - Thompson, George Richard

AU - Patterson, Thomas F.

PY - 2011

Y1 - 2011

N2 - Aspergillosis remains a significant cause of morbidity and mortality. The spectrum of disease is diverse and ranges from noninvasive disease with an excessive immune response, such as in allergic bronchopulmonary aspergillosis (ABPA), to a lack of an immune response as seen in patients with quantitative or qualitative granulocyte deficits and subsequent invasive pulmonary aspergillosis. Noninvasive diagnostic testing has improved the time to initiation of effective antifungal therapy, and numerous agents in different therapeutic classes are now available as treatment options. Voriconazole remains the preferred agent in the treatment of invasive pulmonary aspergillosis, and recent data have increased interest in the potential of combination therapy against this often lethal infection. The role of host genetics in selecting patients that may benefit from more aggressive antifungal prophylaxis or treatment practices remains unclear but is likely to guide therapeutic choices as newer data become available.

AB - Aspergillosis remains a significant cause of morbidity and mortality. The spectrum of disease is diverse and ranges from noninvasive disease with an excessive immune response, such as in allergic bronchopulmonary aspergillosis (ABPA), to a lack of an immune response as seen in patients with quantitative or qualitative granulocyte deficits and subsequent invasive pulmonary aspergillosis. Noninvasive diagnostic testing has improved the time to initiation of effective antifungal therapy, and numerous agents in different therapeutic classes are now available as treatment options. Voriconazole remains the preferred agent in the treatment of invasive pulmonary aspergillosis, and recent data have increased interest in the potential of combination therapy against this often lethal infection. The role of host genetics in selecting patients that may benefit from more aggressive antifungal prophylaxis or treatment practices remains unclear but is likely to guide therapeutic choices as newer data become available.

KW - aspergilloma

KW - Aspergillosis

KW - chronic cavitary aspergillosis

UR - http://www.scopus.com/inward/record.url?scp=83655193171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83655193171&partnerID=8YFLogxK

U2 - 10.1055/s-0031-1295715

DO - 10.1055/s-0031-1295715

M3 - Article

C2 - 22167395

AN - SCOPUS:83655193171

VL - 32

SP - 673

EP - 681

JO - Seminars in Respiratory and Critical Care Medicine

JF - Seminars in Respiratory and Critical Care Medicine

SN - 1069-3424

IS - 6

ER -